GTCbio Revenue and Competitors
Estimated Revenue & Valuation
- GTCbio's estimated annual revenue is currently $4.5M per year.
- GTCbio's estimated revenue per employee is $155,000
Employee Data
- GTCbio has 29 Employees.
- GTCbio grew their employee count by -6% last year.
GTCbio's People
Name | Title | Email/Phone |
---|
GTCbio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is GTCbio?
Welcome to GTC! Follow us to receive updates on our latest conferences and find out how you can connect with decision-makers and influencers in the biotech, life science and pharmaceutical fields! GTC organizes conferences specifically for the biomedical, biotechnology, life science and pharmaceutical industries. Our conferences bring together high-level/influential leaders with decision-making authority from the academia, government, industry, and venture capitalists, and cover a variety of topics, including stem cell therapeutics, infectious diseases, biotech partnering, pharmaceutical litigation, government regulation, bio-based chemicals, drug discovery and development, and many more. Founded in 2002, GTC conferences are designed to stimulate scientific discussions, offer key business insights, and promote partnering and deal-making in the ever-changing biotech and pharmaceutical world.
keywords:N/AN/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.5M | 29 | 0% | N/A |
#2 | $6.7M | 31 | 11% | N/A |
#3 | $3.7M | 31 | -33% | N/A |
#4 | $5M | 32 | 39% | N/A |
#5 | $7.5M | 33 | 10% | N/A |